Successful Combination of Sunitinib and Girentuximab in Two Renal Cell Carcinoma Animal Models: A Rationale for Combination Treatment of Patients with Advanced RCC  by Oosterwijk-Wakka, Jeannette C. et al.
www.neoplasia.com
Volume 17 Number 2 February 2015 pp. 215–224 215
Abbreviati
cG250/gir
density; cc
factor; RIT
Address a
university
PO Box 9
fax: + 31 2Successful Combination of Sunitinib
and Girentuximab in Two Renal Cell
Carcinoma Animal Models:
A Rationale for Combination
Treatment of Patients with
Advanced RCCons: mRCC, metastatic renal cell carcinoma; CAIX, carbonic anhydrase IX;
entuximab, chimeric monoclonal antibody G250; MVD, microvessel
RCC, clear cell renal cell carcinoma; VEGF, vascular endothelial growth
, radioimmunotherapy; TKI, tyrosine kinase inhibitor
ll correspondence to: Jeannette C. Oosterwijk-Wakka, Radboud
medical center, Department of Urology, 267 Experimental Urology,
101, 6500 HB Nijmegen, The Netherlands. Tel.: + 31 243614974;
43541222.Jeannette C. Oosterwijk-Wakka*,
Mirjam C.A. de Weijert*, Gerben M. Franssen†,
WilliamP.J. Leenders‡, JeroenA.W.M. van der Laak‡,
Otto C. Boerman†, Peter F.A. Mulders§ and
Egbert Oosterwijk*
*Radboud University Medical Center, Department of
Urology, 267 Experimental Urology, PO Box 9101, 6500 HB
Nijmegen, The Netherlands; †Radboud University Medical
Center, Department of Nuclear Medicine, PO Box 9101,
6500 HB Nijmegen, The Netherlands; ‡Radboud University
Medical Center, Department of Pathology, PO Box 9101,
6500 HB Nijmegen, The Netherlands; §Radboud University
Medical Center, Department of Urology, PO Box 9101, 6500
HB Nijmegen, The NetherlandsAbstract
Anti-angiogenic treatment with tyrosine kinase inhibitors (TKI) has lead to an impressive increase in progression-
free survival for patients with metastatic RCC (mRCC), but mRCC remains largely incurable. We combined
sunitinib, targeting the endothelial cells with Girentuximab (monoclonal antibody cG250, recognizing carbonic
anhydrase IX (CAIX) targeting the tumor cells to study the effect of sunitinib on the biodistribution of Girentuximab
because combination of modalities targeting tumor vasculature and tumor cells might result in improved effect.
Nude mice with human RCC xenografts (NU12, SK-RC-52) were treated orally with 0.8 mg/day sunitinib, or vehicle
for 7 to 14 days. Three days before start or cessation of treatment mice were injected i.v. with 0.4 MBq/5 μg 111In-
Girentuximab followed by biodistribution studies. Immunohistochemical analyses were performed to study the
tumor vasculature and CAIX expression and to confirm Girentuximab uptake.
NU12 appeared to represent a sunitinib sensitive tumor: sunitinib treatment resulted in extensive necrosis and
decreased microvessel density (MVD). Accumulation of Girentuximab was significantly decreased when sunitinib
treatment preceded the antibody injection but remained unchanged when sunitinib followed Girentuximab
injection. Cessation of therapy led to a rapid neovascularization, reminiscent of a tumor flare. SK-RC-52 appeared
to represent a sunitinib-resistant tumor: (central) tumor necrosis was minimal and MVD was not affected. Sunitinib
treatment resulted in increased Girentuximab uptake, regardless of the sequence of treatment. These data indicate
that sunitinib can be combined with Girentuximab. Since these two modalities have different modes of action, this
combination might lead to enhanced therapeutic efficacy.
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Renal cell carcinoma accounts for approximately 3% of all cancers and was
diagnosed in over 115,000 individuals in Europe in 2012 [1]. Most RCC
(70%) are of the clear cell type (ccRCC) that is characterized by high
expression levels of Vascular Endothelial Growth Factor (VEGF) and,
consequently, a hypervascular phenotype. Over the last few years, anti-
VEGF therapies have significantly changed the standard of care for patients
with advanced RCC [2]. Sunitinib [3], sorafenib [4], axitinib [5],
pazopanib [6] and bevacizumab + interferon [7] have all been registered for
the treatment of advanced RCC. Additionally, the mTOR inhibitors
Temsirolimus and Everolimus have been registered for poor risk RCC
patients [8,9]. Implementation of these new treatment modalities has lead
to an impressive increase in progression-free survival [10]. Nevertheless,
because eventually treatment resistance occurs, metastatic RCC remains
largely incurable. Additionally these chronic treatments may coincide with
significant toxicity which increases to unacceptable levels when combina-
tion treatment is applied [11]. Sequential therapy may be more promising
but the most optimal sequence therapy has not been established.
There is considerable evidence that anti-VEGF and anti-VEGF
receptor (VEGFR) drugs cause remodeling of the aberrant tumor
vessels, resulting in a “normalized vasculature” [12]. This phenom-
enon may improve tumor perfusion and reduce tumor interstitial
fluid pressure, thereby improving uptake of other drugs. Indeed,
addition of bevacizumab to first-line chemotherapy in advanced
colorectal cancer resulted in an overall survival benefit [13]. However,
caution is warranted regarding unanticipated effects since studies with
VEGFR-targeting compounds in murine models provided evidence
for increased metastatic propensity [14,15].
Chimeric monoclonal antibody G250 (cG250/Girentuximab) targets
human carbonic anhydrase IX (CAIX), a transmembrane protein which
catalyzes the reaction CO2 + H2O↔HCO3
−+ H+. Expression of CAIX is
regulated by hypoxia-inducible factor 1-alpha,which in turn is regulated by
theVonHippel Lindau (VHL) protein (pVHL), a gene affected in the vast
majority of ccRCCpatients. Themolecular link between pivotalmolecular
events in ccRCC explains the ubiquitous expression ofCAIX in ccRCC. In
non-RCC tumors, CAIX is activated following hypoxia. In view of the
favorable tissue distribution, the potential of CAIX targeting of RCC for
diagnosis or therapy has been studied extensively [16–19]. Clinical trials
have demonstrated high, specific tumor accumulation of Girentuximab,
and radioimmunotherapy (RIT) with 177Lu-Girentuximab can stabilize
previously progressive metastatic ccRCC [20]. Combination of sunitinib
with 177Lu-Girentuximab RIT may act synergistically since these
compounds simultaneously target the tumor blood vessel- and tumor
cell compartment in patients withmRCC.We have previously shown that
simultaneous administration of sunitinib and Girentuximab severely
compromised mAb accumulation in mice [21], an effect that could be
reiterated in patients treated with sorafenib [22]. However, shortly after
discontinuation of tyrosine kinase Inhibitor (TKI) treatment, mAb
accumulation was restored, mainly in the tumor periphery [21]. This
suggests that sequential administration of TKIs and Girentuximabmay be
better than simultaneous administration. The aim of this study was to
explore how tumor targeting by Girentuximab is influenced by sunitinib
treatment in sequential treatment protocols.Material and Methods
Cell lines and Reagents
The human Renal Carcinoma cell line SK-RC-52 was established
from a mediastinal metastasis of a primary RCC [23]. The cell linewas cultured in RPMI1640 (Gibco, Bleiswijk, The Netherlands)
supplemented with 10% fetal bovine serum (Sigma, Zwijndrecht,
The Netherlands) and 2 mM glutamine (Gibco). Human renal cell
carcinoma xenograft model NU12 [24] was maintained by passing
freshly excised tumor pieces (1 to 2 mm3) subcutaneously (s.c.) in
mice. Both SK-RC-52 and NU12 express high levels of CAIX[25].
Conjugation and Radiolabeling of Girentuximab
The isolation, characteristics and the immunohistochemical
reactivity of mouse mAb G250 (mG250) have been described earlier
[26]; mAb G250 has a high affinity for CAIX (Ka = 4 × 109 M−1)
which is expressed on the cell surface of N95% of ccRCC and absent
on most normal tissues. The generation of Girentuximab has been
described elsewhere [27].
The conjugation of Girentuximab (generously provided by Wilex
AG, München, Germany) to ITC-DTPA has been described earlier
[28]. The Girentuximab-ITC-DTPA conjugate (1 mg/ml) was
radiolabeled with 111InCl3 (Mallinckrodt, The Netherlands) as
described previously [28].
After PD10 purification the radiochemical purity of the 111In-
Girentuximab preparations was determined using ITLC silica gel
strips (Biodex, Shirley, NJ) and 0.1 M citrate buffer pH 6.0 as the
mobile phase. The radiochemical purity was 97 ± 3%. The
immunoreactive fraction (IRF), determined on freshly trypsinized
SK-RC-52 RCC cells at infinite antigen excess essentially as described
by Lindmo et al. [29] with minor modifications [27], was 87 ± 7%.
Animal Experiments
Institutional guidelines were strictly followed for maintenance of
animals and experimental procedures were approved by the
Institutional Animal Care and Use Committee (IACUC). Female
BALB/c nu/nu mice, 6 to 8 weeks of age, were obtained from Janvier,
France, and maintained at the local central animal facility. Animals
were either grafted s.c. with freshly excised NU12 RCC xenograft
pieces [24] of approximately 1 to 2 mm3 or injected s.c. with 2*106
freshly trypsinized SK-RC-52 cells. Treatment with sunitinib
(SU11248, Sutent®, Pfizer, NY) was started when tumors had
reached a tumor volume of 100 to 200 mm3.
Sunitinib was dissolved in 0.1 M Na-citrate, pH 4.5 and freshly
prepared every week.
Mice received the equivalent of 40 to 50mg/kg (0.8 to 1 mg/200 μl)
sunitinib or vehicle orally per day for 7 to 14 days.
Biodistribution Studies and SPECT/CT Analysis
Once tumors reached the desired volume, mice were divided into
groups of 4 to 5 mice (in one experiment 8 to 9mice). Mice were treated
with sunitinib or vehicle control every day for 7 to 14 days. Mice were
injected intravenously with 111In-Girentuximab (0.4MBq, 5 μg) 3 days
pre-sunitinib or 3 days post-sunitinib treatment. Mice were euthanized
3, 7, 10, 14 or 17 days post Girentuximab injection. Alternatively, mice
were injected intravenously with 111In-Girentuximab (0.4 MBq, 5 μg)
3, 7 or 10 days post-sunitinib treatment. Mice were euthanized 3 days
post-injection. Animals were dissected, tissues harvested (tumor, blood,
muscle, liver, spleen, kidney, stomach, lung, colon, small intestine),
weighed and counted in a gamma counter (Wizard; Pharmacia-LKB,
Perkin-Elmer, Boston,MA). The activity in the samples was expressed as
% injected dose per gram tissue (%ID/g).
SPECT/CT analysis was performed to visualize the biodistribution
and the intra-tumoral distribution of the radiolabeled antibody; Sixteen
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specific activity of 22,5 MBq/5 μg, 3 days before start or 3 days after
stop of treatment with sunitinib or vehicle for 7 days. SPECT/CT
analysis (USPECT-II/CT scanner (MILabs, Utrecht, TheNetherlands)
was performed 3, 7 or 14 days after injection of the radiolabeled
antibody with a 1.0-mm-diameter pinhole rat collimator tube. The
animals were placed in the scanner in supine position. SPECT scans
were acquired for 30 to 120 min, followed by CT scans for anatomic
reference (65 kV; 612 μA; exposure time, 240 ms). was performed 3, 7
or 14 days after injection of the radiolabeled antibody.
Antibodies and Immunohistochemical Analysis
Harvested tumors were snap-frozen and stored at −80°C. 4-μmcryostat
sections were cut and stored at −80°C until use. Haematoxylin-eosin
staining was performed for morphological analysis of the tumors.
Primary antibodies used were: Girentuximab (Wilex, Germany, 10
μg/ml), rat-anti-mouse mAb 9 F1, hybridoma supernatant 1:50 [30],
and rabbit-anti-human mAb Ki67 (clone sp6/RM-9106-S, Thermo
Scientific, Astmoor Runcorn, UK, 1:200). All antibodies were diluted
in 1% BSA in 50 mM phosphate buffered saline, pH 7.4 unless
mentioned otherwise.
For visualization of CAIX expression, sections were acetone fixed
and incubated with Girentuximab, washed and incubated with
peroxidase (PO) conjugated rabbit-anti-human IgG (P214, Dako,
Heverlee, Belgium),1:100 as secondary antibody. To detect in vivo
accumulated injected Girentuximab, cryostat sections were incubated
with rabbit-anti-human IgG–PO only. Antibody 9 F1 was used to
detect mouse endothelial cells. After acetone fixation, primary
antibody 9 F1 was applied for 1 h at RT. After washing, secondary
antibody Goat-anti-rat-PO (Sigma) 1:100, supplemented with 4%
normal mouse serum, was applied. All sections were developed with
powerDAB (Immunologic, Duiven, The Netherlands) and counter-
stained with haematoxylin. Microscopic evaluation was performed on
an Axioskop microscope (Zeiss, Sliedrecht, The Netherlands) and
pictures were taken with the Axiocam mrc5 (Zeiss) with Axio vs40
version 4.8 2.0 software (Axiovision, Zeiss).
Triple immunofluorescence was performed to visualize cell
proliferation and endothelial cells simultaneously. After acetone
fixation, cells were pretreated for 30 min with 1% BSA/0.2 %Triton
X100 in PBS. Subsequently sections were incubated overnight at 4°C
with an antibody cocktail consisting of Ki67 and 9 F1 diluted in 1%
BSA/0.2 %Triton X100 in PBS. After washing, sections were
incubated with the secondary antibody cocktail consisting of goat-
anti-rabbit Alexa 568, 1:200 and goat-anti-rat Alexa 488, 1:200
(Molecular probes, Life technologies, Bleiswijk, The Netherlands).
Finally, sections were incubated with DRAQ5 (Biostatus DR50051,
Leicestershire, UK, 1:200) to visualize nuclei. Microscopic evaluation
of triple immunofluorescence was performed on a high content
microscope (Leica, Rijswijk, The Netherlands, DMI6000B inverted
microscope extended with a motorized x-y scanning stage, Leica
EL6000 illumination source), equipped with a high-resolution Leica
DFC360 FX CCD camera.
Microvessel Density Measurements
Density of microvascular profiles was assessed automatically as
described previously [31] using an AxioCam MRc connected to an
AxioPhot microscope (Zeiss). Images were acquired using a 20x
objective (Plan Apochromat, NA = 0.32), resulting in a specimen
level pixel size of 0.53 μm.Microvessel density (MVD) was defined asthe percentage of microvessel area/total tumor area. All image
acquisition and processing was performed using custom written
macros in KS400 image analysis software (Zeiss).
RT-PCR
VEGF-A/RT-PCR was performed on NU12 and SK-RC-52 cells as
well as on harvested xenografts of both sunitinib-treated as control
animals. Total RNA was isolated from frozen tumor sections or cultured
cells using TRIzol Reagent (Life Technologies), according to the
manufacturer's protocol. RNA integrity was checked by 1.0% agarose gel
electrophoresis. RNA samples (2 μg) were DNAse treated (Invitrogen,
Life Technologies) and reverse-transcription was performed at 42°C for
60 min, using SuperScripttm II (Invitrogen). Two μl of the reaction
product was subjected to standard PCR amplification using Super Taq
polymerase (Sphaero, Gorinchem, The Netherlands) and VEGF-A-
primers 5′-GCA CCC ATG GCA GAA GGA GGA-3′ (sense) and 5′-
TCA CCG CCT CGG CTT GTC AC-3′ (exon 8 specific, antisense).
Reaction mixture was heated 1 min at 94°C followed by 30 cycli for 30 s
at 94°C, 1 min at 61°C, 1 min at 72°C and 10 minutes at 72°C.
This primer set amplifies all VEGF-A isoforms simultaneously,
except VEGF165b. Expected product lengths with this primer set are
367 bp (VEGF-121), 436 bp (VEGF-145), 496 bp (VEGF165) and
568 bp (VEGF189). cDNAs were also subjected to a PCR for
GAPDH as control housekeeping gene. VEGF165b was analyzed in a
separate RT-reaction with forward primer as mentioned above and a
reverse primer recognizing an alternative exon in VEGF: 5’-TCA
GTC TTT CCT GGT GAG AGA TCT GCA-3’.
Statistical Analysis
Results are presented as means with standard deviations (SD). For
the statistical analysis, all sunitinib treated animals were clustered
together to increase the number of animals. This was also done with
the control animals. Differences in Girentuximab uptake and MVD
between treatment and control mice at each time-point were tested
for statistical significance using the two-way ANOVA with factors
treatment, time and interaction. When interaction was not significant
it was removed from the model and two-way ANOVA without
interaction was applied. P b 0.05 was considered significant.
Results
Decreased Uptake of 111In-Girentuximab andDecreasedMicro
Vessel Density when Mice with NU12 Tumors were Treated
with Sunitinib
Treatment of NU-12 tumors with sunitinib caused substantial
decrease of tumor growth (P b 0.05; Figure S1). In SK-RC-52,
sunitinib treatment resulted in stabilization of tumor growth (p = 0.056;
Figure S2). To study the influence of sunitinib treatment on the tumor
uptake of Girentuximab, biodistribution studies were performed using
111In-Girentuximab in BALB/c athymic mice xenografted with NU12
or SK-RC-52 (Figure 1 and Supplementary Tables S1-S5). In the
NU12 model, tumor uptake of 111In-Girentuximab decreased when
sunitinib treatment preceded the antibody injection (Figure 1A; p b
0.005 and Supplementary Table S1). Because previous experiments
have shown that Girentuximab uptake inversely correlates with tumor
volume [32], and sunitinib stabilizes tumor growth, Girentuximab
uptake was plotted for individual tumors. This analysis demonstrated
that at similar tumor volumes antibody uptake in the tumors of
sunitinib-treated mice was lower than that in the control mice, most
notably at day 10 (Figure 1C).
Figure 1. Biodistribution of cG250 in nude mice with NU12 and SK-RC-52 tumors.111In-Girentuximab biodistribution in BALB/c nu/nu mice
shows decreased uptake with sunitinib in NU12 tumors and increased uptake with sunitinib in SK-RC-52 tumors. Treatment schedules
shown on top of graphs.Groups of 4–5 mice (in F: 8–9 mice) were treated with sunitinib every day for 1 week (A,D,F) or until they were
euthanized (B,E). Three days before start or 3d (in one experiment also 7 or 10 days) after stop of treatment, mice were injected with 111In-
Girentuximab (0.4 MBq, 5 μg) and mice were euthanized at various timepoints. The activity in the samples was expressed as % injected
dose per gram tissue (%ID/g). A: Biodistribution of NU12 mice with sunitinib treatment preceding 111In-Girentuximab injection, B:
Biodistribution of NU12 mice injected with 111In-Girentuximab before sunitinib treatment, C: G250 antibody uptake was plotted for
individual tumors from experiment. Red open circles: control tumors; black closed circles: sunitinib treated tumors A, D: Biodistribution
of SK-RC-52 mice treated with sunitinib preceding 111In-Girentuximab injection, E: Biodistribution of SK-RC-52 mice treated with sunitinib
followed by 111In-Girentuximab, F: Biodistribution of SK-RC-52 mice with 111In-Girentuximab injection 3 days, 7 days or 10 days after
cessation of sunitinib, G: G250 antibody uptake was plotted for individual tumors from experiment F. *P b .05, **P b .01, ***P b .005. P-
values shown for the biodistribution are based on all sunitinib treated animals (N = 15, 9, 28,18, 25 for Figure 1, A, B, D–F, respectively)
compared to all control animals (N = 13, 16, 30, 18, 27 for Figure 1, A, B, D–F, respectively).
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not influence antibody uptake in the NU12 model (Figure 1B, p =
0.7959 and Supplementary Table S2, Figure S3). Tumors were
analyzed by immunohistochemistry (IHC) for the presence of
vasculature, CAIX expression and intratumoral distribution of
Girentuximab (Figures 2, 3). Extensive necrosis was observed in the
majority of sunitinib treated NU12 tumors, as judged by HE staining
(Figure 2E). Necrosis was minimal in untreated tumors. (Figure 2A).
CAIX, the Girentuximab target, was expressed in all viable NU12
tumor cells, regardless of sunitinib treatment (Figure 2B, F).
Interestingly, CAIX could still be detected in necrotic tumor areas.
In accordance with earlier studies, homogeneous accumulation of
Girentuximab was observed in non-treated NU12 tumors(Figure 2C). NU12 tumors harvested from non-treated animals
were well vascularized (Figure 2D). In contrast, NU12 tumors of
sunitinib-treated mice displayed extensive central necrosis and
Girentuximab accumulation was limited to the rim of the tumors
(Figure 2G). Quantitative microscopic analysis confirmed that the
viable tumor area was markedly reduced in tumors from sunitinib-
treated animals. Microvessel density in the centre of these tumors
was very low as compared to control tumors (Figure 3A, p b 0.001),
whereas in the viable tumor rim a rebound effect was seen
(Figure 2H). Triple immunofluorescence staining for cell prolifera-
tion, endothelial cells and nuclei revealed low proliferation index of
NU12 tumor cells, both in control as well as in tumors of sunitinib-
treated mice (Figure 3C and D respectively).
Figure 2. Phenotypic analysis of NU12 and SK-RC-52 tumors.Phenotypic analysis of NU12 and SK-RC-52 tumors of mice treated with
sunitinib shows necrosis, decreased accumulated cG250 and decreased number of microvessels in NU12 tumors and very limited
necrosis, increased accumulated cG250 and unchanged number of microvessels in SK-RC-52 tumors.A-D, NU12 control tumors; E-H,
NU12 sunitinib treated tumors; I-L, SK-RC-52 control tumors; M-P, SK-RC-52 sunitinib treated tumors. HE staining in A, E, I and M.
Sunitinib treatment did not modify CAIX expression in either NU12 or SK-RC-52 (B,F and J,N). In NU12 control tumors (A-D), homogeneous
accumulation of cG250 (C) was observed. D: tumor vasculature visualized by staining with 9 F1. In sunitinib treated NU12 tumors (E-H),
extensive necrosis was present as judged by HE (E) and accumulated cG250 (G) and microvessels (H) were only observed in the tumor
rim. SK-RC-52 control tumors (I-L), revealed focal accumulation of injected cG250 (J) and moderate microvessel density (MVD) as
visualized by staining with 9 F1 (L). Accumulation of cG250 was increased in sunitinib treated SKRC52 tumors (O vs. K) andMVD appeared
to be increased (P vs. L). Necrosis was limited regardless of treatment (I, M). N: necrosis. Original magnification ×25 and ×200.
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Figure 3. Microvessel density analysis.Density of microvascular profiles was assessed automatically as described previously [31] using
an AxioCam MRc connected to an AxioPhot microscope (Zeiss). Microvessel density (MVD) was defined as the percentage of
microvessel area/total tumor area. All image acquisition and processing was performed using custom written macros in KS400 image
analysis software (Zeiss). Sunitinib treatment resulted in significant decrease in% of microvessels in NU12 tumors (A) but no change in%
of microvessels in SK-RC-52 tumors (B). Triple immunofluorescence staining of NU12 control (C) and sunitinib treated tumor (D) and SK-
RC-52 control (E) and sunitinib treated tumor (F). Low proliferation of NU12 tumor cells (nuclei in blue as visualized by DRAQ5) as
visualized by Ki67 staining (red) is observed, both in controls (C) as well as in sunitinib treated tumors (D). Please note decrease of
endothelium (9 F1 staining) in sunitinib treated NU12 tumor (green). In SK-RC-52, Triple immunofluorescence staining revealed high
proliferation of SK-RC-52 tumor cells, both in controls (E) as well as in sunitinib treated tumors (F) Necrosis was minimal. ****P b .001.
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Vessel Density when Mice with SK-RC-52 Tumors were Treated
with Sunitinib
Sunitinib treatment of mice bearing SK-RC-52 tumors affected
Girentuximab accumulation regardless of the sequence: Antibody
uptake in the tumors of the sunitinib-treated animals was higher than
in untreated animals (Figure 1D, E, p = 0.0059 and p = 0.026
respectively, Supplementary Tables S3, S4). Plotting of antibody
accumulation against the tumor volume demonstrated that at similar
tumor volumes Girentuximab uptake in tumors of sunitinib-treated
mice was higher than or at least equal to tumor uptake in control mice
(Figure 1G). To establish whether extension of the time interval
between sunitinib treatment and antibody injection would improve
Girentuximab tumor accumulation, mice were injected withGirentuximab 3, 7 and 10 days post-sunitinib, and were euthanized
3 days later (6, 10 and 13 days, respectively). In all cases
Girentuximab accumulation in the SK-RC-52 tumor was higher in
sunitinib-treated animals (Figure 1F, p = 0.0114, Supplementary
Table S5). Extension of the time interval beyond 3 days did not
further improve antibody accumulation.
Occasionally necrosis was observed in SK-RC-52 tumors in
untreated and in sunitinib treated animals (Figure 2I, M).
Immunohistochemical analysis of SK-RC-52 tumors revealed
homogeneous CAIX expression regardless of sunitinib treatment
(Figure 2J, N). Control tumors showed focal elevated accumulation
of Girentuximab (Figure 2K) and moderate MVD, as visualized by
staining with 9 F1 (Figure 2L). Accumulation of Girentuximab was
higher in sunitinib-treated SK-RC-52 tumors (Figure 2O) but MVD
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immunofluorescence staining revealed high proliferation index of SK-
RC-52 tumor cells, both in controls as well as in sunitinib-treated
tumors (Figure 3E and F respectively).
In previous studies we have shown that Girentuximab is
internalized relatively rapidly by SK-RC-52 cells [33] precluding
detection of Girentuximab beyond day 3 by immunohistochemistry.
To investigate the distribution of the radiolabeled antibody in the
animals, SPECT/CT analysis was performed. In agreement with the
biodistribution results, more radiolabel was observed in the sunitinib
treated SK-RC-52 than in control tumors (Figure 4A). The
localization of the radiolabeled antibody was not restricted to a
specific compartment in the tumor, but rather distributed homo-
genously throughout the tumor. No differences between the various
treatment groups were observed (Figure 4B).
VEGF Expression of NU12 and SK-RC-52 Tumors
In view of the observed differences between the two RCC xenograft
models, we investigated VEGF-A expression as different VEGF-AFigure 4. SPECT/CT imaging of mice with SK-RC-52 tumors.SPECT/C
intra-tumoral distribution of the radiolabeled antibody. Sixteen mice b
with 111In-Girentuximab with a specific activity of 22,5 MBq/5 μg, 3
images of mouse bearing SK-RC-52 tumor on right flank (arrow) at 7 d
uptake, minimal uptake in other organs was observed. More radiolab
This is in concordance with the biodistribution data. In all groups rad
radiolabel distribution was observed in the various treatment groupsexpression levelsmight explain the observed differences.Non-quantitative
RT-PCR did not show differences in VEGF-A expression in both tumor
models, regardless of sunitinib treatment (Figure 5).
Discussion
Sunitinib treatment can result in significant tumor control in
approximately 40% of patients with mRCC [34]. This is a major
improvement in the clinical management of these patients as overall
survival (OS) of responding patients is significantly improved [34].
However, the prognosis of non-responding patients remains poor with a
mean OS of 14.5 months [34]. Therapy with other TKI, mTOR
inhibitors and Bevacizumab + Interferon show similar results [35].
Unfortunately, TKI combination therapies are not feasible due to
unacceptable toxicity and therefore current efforts are aimed at
sequential therapy regimens and/or the combination of surgery and
TKI treatment [11]. Moreover, therapy resistance occurs almost
inevitably in all patients, highlighting the need for other therapies.
Combination therapy aiming at different tumor components such as
tumor vasculature and the tumor cells might improve therapy outcome.T analysis was performed to visualize the biodistribution and the
earing SK-RC-52 were treated with sunitinib for 7 days and injected
days before start or 3 days after stop of treatment. Micro-SPECT
after injection of 111In-girentuximab show that in addition to tumor
el was observed in the sunitinib treated tumors than in vehicle (A).
iolabel was distributed throughout the tumor and no difference in
(B).
Figure 5. Expression of VEGF-A isoforms in NU12 and SK-RC-52
tumors.VEGF-A/RT-PCR was performed on NU12 and SK-RC-52
cells as well as on harvested xenografts of both sunitinib-treated
(from 2 days up to 7 days) as untreated animals.After correction for
loading differences (as judged by GAPDH), no differences in VEGF-
A expression was observed between tumor models, regardless of
sunitinib treatment.
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[36]. Diagnostic images with Girentuximab, an antibody which
targets CAIX, were superior to CT [37], and radioimunotherapy with
177Lu-labeled Girentuximab resulted in disease stabilization [20] The
failure to significantly influence disease progression and lack of
partial/complete responses might be due to the tumor bulk present.
Additionally, central regions of larger tumor masses might be less
accessible for girentuximab, as central regions are poorly perfused.
Unfortunately adjuvant treatment of nephrectomized RCC patients
with unlabeled Girentuximab who have a high risk of relapse
(ARISER trial) did not meet its primary endpoint: improvement in
median DFS. However, with increasing CAIX expression in tumor
tissue, as quantified by a CAIX score, the treatment was more effective
[38]. Possibly only high density CAIX RCC cells can be killed by
antibody-dependent cellular cytotoxicity in this adjuvant setting.
The combination of Girentuximab, aimed at tumor cells and
sunitinib, aimed at the tumor vasculature, might therefore lead to
superior therapy outcome. However, simultaneous administration of
sunitinib and Girentuximab severely compromised mAb accumula-
tion [21]. Since the anti-tumor effect of Girentuximab depends on
tumor cell accessibility from the vascular compartment, we studied
the effect of sunitinib on the biodistribution of Girentuximab when
administered with a short time delay between sunitinib and antibody
administration. This short drug holiday mimics TKI treatment cycles
in men and might allow re-establishment of the tumor vasculature,
which would permit adequate mAb delivery and accumulation.
In the NU12 model, sunitinib treatment followed by a 3-day drug
holiday resulted in a reduction in antibody uptake in the tumor.
Microscopic analysis showed that the amount of viable tumor cells
was considerably lower in sunitinib-treated tumors, apparently due to
massive destruction of tumor microvessels. This decrease in antibody
uptake was less pronounced than when the antibody was adminis-tered at the same time as the sunitinib treatment [21]. Thus, a time
delay between sunitinib treatment and antibody administration did
increase Girentuximab uptake, albeit that accumulation did not reach
the level of untreated controls. The reduced antibody uptake is
probably due to the accessibility of fewer viable cells in the NU12
tumors in sunitinib-treated animals, while tumor volume was not
affected. Despite the presence of CAIX in necrotic areas after
sunitinib treatment, Girentuximab did not accumulate in those areas,
showing that the vasculature in the necrotic regions was not restored.
The results suggest that despite the lower Girentuximab uptake in the
tumor, all viable tumor cells present at the tumor periphery are
targeted. Antibody uptake was not affected when administered before
sunitinib treatment. This is not unexpected because the pharmaco-
kinetics of the mAb in sunitinib treated animals were not affected:
maximum and homogeneous accumulation can be established before
treatment with sunitinib is initiated. This suggests that sunitinib after
Girentuximab administration might be preferred over sunitinib
before Girentuximab injection. However, in this scenario almost all
tumor cells are viable and the amount of targeted Girentuximab
molecules per viable tumor cell is substantially lower. This will
amount to higher radiation levels per tumor cell with Girentuximab-
guided radioimmunotherapy. Thus, viable tumor cells remaining at
the tumor rim after anti-angiogenic therapy can be efficiently targeted
and potentially lethally damaged when Girentuximab radioimmu-
notherapy is applied.
Unexpectedly, antibody uptake in the SK-RC-52 tumors increased
in the sunitinib treated animals, regardless of sequence of the
treatment. In contrast to NU12, tumor cell viability was not affected
by sunitinib treatment. The increased uptake in combination with
unchanged MVD after sunitinib treatment suggests functional
changes in the microvasculature in this tumor. The increased uptake
was not only the consequence of the smaller tumor volume, as tumors
with comparable volumes of sunitinib-treated animals showed equal
or higher tumor uptake of Girentuximab. Whether the increased
uptake is the consequence of tumor vessel normalization (and reduced
interstitial fluid pressure) as suggested in previous studies [39,40] or
the consequence of increased vascular permeability is unclear.
Also in this model sunitinib treatment before antibody injection
appears preferable when combination therapy is considered:
Girentuximab uptake post-sunitinib is significantly higher than
Girentuximab uptake pre-sunitinib.
The two RCC models used in the present studies might be very
valuable in studying resistance to TKI, a phenomenon occurring in
most mRCC patients as they appear to reflect the extremes that can be
observed in patients: some patients respond favorably, whereas other
patients do not respond. Also, in some mRCC patients unexpected
rapid progression and tumor related complaints after discontinuation
of oral angiogenesis inhibitors can be observed [41]. This might be
explained by an increase of vascular density, tumor blood flow rate
and vascular permeability. In NU12 tumors a substantial part of the
tumor endothelium is destroyed after sunitinib treatment, represen-
tative of a highly sensitive tumor, and cessation of therapy led to a
rapid neovascularization, reminiscent of a tumor flare. SK-RC-52
appears to represent a sunitinib-resistant tumor, with little impact of
sunitinib treatment on the microvessel density, but with physiological
changes of blood vessels, in concordance with the hypothesis put
forward by Jain et al. [12].
The disparity to sunitinib treatment between these models is
striking. Because the vasculature of the two xenograft models has the
Neoplasia Vol. 17, No. 2, 2015 Successful combination of sunitinib and Girentuximab in RCC Oosterwijk-Wakka et al. 223same murine origin, this implies that the differences might be due to
different angiogenic gene expression profiles in the tumors. Non-
quantitative RT-PCR did not demonstrate any difference in VEGF-A
expression levels between sunitinib-treated and non-treated NU12
cells and SK-RC-52 cells nor between NU12 xenografts and SK-
RC-52 xenografts. Also gene expression profiles of SK-RC-52 and
NU12 determined with the RT2 Profiler™ PCR Array Human
Angiogenesis (PAHS-24Z, Qiagen) did not show differences in
VEGF-A expression (Ct 22.0 and 20.4, respectively). In this assay 5
genes involved in angiogenesis were differentially expressed between
NU12 and SK-RC-52. VEGF-C levels were ~100-fold lower in
NU12 cells compared to SK-RC-52. VEGF-C is one of the main
growth factors implicated in lymphangiogenesis, signals through
VEGFR-3 and plays a secondary role in angiogenesis. Expression
levels of placental growth factor (PGF), a homolog to vascular
endothelial growth factor and PTGS1 (prostaglandin-endoperox-
idase synthetase 1) were higher in NU12. PGF can function as
decoy receptor for VEGF which may explain the observed sunitinib
sensitivity of NU12. EFNA1 and PLAU were over-expressed in the
non-responder cell line SK-RC-52. EFNA1 is a member of the
ephrin (EPH) family, comprising the largest subfamily of receptor
protein-tyrosine kinases. High EFNA1 levels may aid cells in resisting
TKI challenge. Moreover, high plasminogen activator urokinase
(PLAU) levels support fractional survival of cancer cells [42]. Also,
expression levels of placental growth factor (PGF), a homolog to vascular
endothelial growth factor and PTGS1 (prostaglandin-endoperoxidase
synthetase 1) were lower in SK-RC-52 as in NU12. Collectively, the
high expression of EFNA1 and PLAU together with low expression of
PGF and PTGS1 may explain the resistance of SK-RC-52 in
comparison to NU12.
Anti-angiogenic therapies can reduce tumor perfusion and uptake of
chemotherapeutics: bevacizumab treatment of patients with non-small
cell lung cancer showed rapid and significant reduction of tumor
perfusion and docetaxel uptake [43]. Moreover, preclinical (ovarian and
esophageal cancer) and clinical studies (RCC) with bevacizumab [44]
and sorafenib [45] demonstrated that antibody-uptake in the tumor is
hampered when administered immediately after cessation of anti-
angiogenic therapy. The investigators emphasize that administration
schedules should be carefully designed to optimize combination
treatment of anti-angiogenic therapy with other treatment modalities.
Our results show that TKI andmAbs can be combined, provided a short
drug holiday is introduced, regardless of TKI sensitivity: for TKI sensitive
tumors TKI treatment leads to central necrosis and Girentuximab can
then effectively target the remaining viable RCC cells in the tumor,
whereas in TKI-resistant tumors Girentuximab tumor accumulation is
increased, leading to a higher antibody levels and correspondingly higher
radiation dose in the tumor. Because TKI andGirentuximab are directed
against different target cells, and the toxicity profile differs, combination
of both drugs might prove beneficial. Stabilization of previously
progressive mRCC appears possible with 177Lutetium-Girentuximab
and combination with TKI might lead to better and durable responses.
In view of our results, initial treatment with TKI followed by
177Lutetium-Girentuximab may be better than the reverse: administra-
tion of Girentuximab to patients with TKI-sensitive tumors will lead to
massive cell death and the remaining viable cells in the tumor periphery
will be effectively targeted by the radiolabeled antibody, whereas
administration of Girentuximab to patients with TKI-insensitive tumors
will lead to more effective 177Lutetium-Girentuximab accumulation,
resulting in higher radiation doses.Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2014.12.011.
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